Galapagos Readies Two Clinical Trials To Advance Filgotinib as IBD Treatment

Galapagos Readies Two Clinical Trials To Advance Filgotinib as IBD Treatment
Galapagos has completed discussions with U.S. and European regulatory authorities to begin the DIVERSITY Phase 3 clinical trial (NCT02914561) in patients with Crohn’s disease and the SELECTION Phase 2b/3 study (NCT02914522) in ulcerative colitis with filgotinib. Filgotinib is a selective inhibitor of the JAK1 (Janus kinase 1), an enzyme involved in the signaling pathways of several pro-inflammatory

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *